24 Aug Top 3 health new items

When you look after yourself, you feel better. Healthcare is important for everybody. In fact, medical translators are always trying to help people understand the latest medical research. In this article, we’ll share with you the top 3 health-related news items it is worth knowing about. 

Giving birth during a pandemic

More people are choosing telemedicine for their healthcare needs during the pandemic, but there are still gaps in the coverage.  In terms of contraception, telehealth has proved an effective option for women trying to access the healthcare they need while trying to avoid visiting a healthcare facility in person. Unfortunately, access to telehealth services can be a significant challenge for women with limited incomes or those living in rural areas where access to reliable internet services is a challenge many cannot overcome.

Coronavirus symptoms

New research from South Korea has shown that people infected with the new coronavirus but who are asymptomatic carry just as much of the virus in their throat, lungs and nose as those who do have symptoms. The studyTrusted Source, which was published on Thursday in JAMA Internal Medicine, also discovered that on average, it took asymptomatic people 17 days to test negative for the virus after diagnosis, whereas it took symptomatic people 19 to 20 days.

These new findings add to the growing belief that asymptomatic carriers may potentially be able to spread the virus just as readily as those who do have symptoms.

Preventing multiple Sclerosis 

A new drug for treating relapsing multiple sclerosis (MS) is showing some promise. More than 900 patients received an injectable drug called ofatumumab in a phase III multicentre clinical trial. The study results were published last week and the immune-modulating drug was shown to reduce inflammatory disease activity. Researchers said a subcutaneous injection of ofatumumab produced a significant reduction in new inflammation as well as fewer clinical relapses and progression events.

In the second year of treatment, nearly 9 out of 10 study participants on ofatumumab showed no sign of disease activity.